Project Grant R21AI190149
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$432K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $466,125.00 to New York University (NYU) to elucidate the molecular process of orthopox virus entry, including the interactions between viral and cellular proteins during attachment and entry, as well as the accessibility of viral entry proteins to antibodies. The project aims to provide unprecedented detail on how...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $221,105.00 to the University of Arkansas for Medical Sciences to investigate how APOBEC3 enzymes impact poxvirus evolution, with a focus on Monkeypox (MPOX) virus. The research aims to elucidate the mechanisms by which APOBEC3 enzymes drive MPOX genome diversification, which could enable prediction of MPOX evolution...
This $199,775 Project Grant from the National Science Foundation Division of Environmental Biology will support research at the University of California, Los Angeles to develop models to understand and predict the spread of monkeypox virus. The research will analyze monkeypox virus surveillance data and transmission patterns in both core and non-core populations. Mathematical models will be built to design disease control strategies, such as comparing outcomes from reducing transmission in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $193,336 to The Johns Hopkins University to assess factors associated with monkeypox (MPOX) vaccination, testing, and stigma among men who have sex with men (MSM) in the United States. Specifically, the study aims to: 1) evaluate determinants and disparities of MPOX vaccination among MSM; 2) characterize differences in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,160 to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The grant aims to evaluate the protective efficacy of various vaccine antigens, including PFS25, PFS230, PFCSP, PVS25, and a chimeric PVCSP, both individually...
The federal Project Grant award R01AI189313 for $905,998.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research by the Texas Biomedical Research Institute to evaluate the safety, immunogenicity, and efficacy of an attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the setting of HIV co-infection, using rhesus and cynomolgus macaque models. The goal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $720,588 to the Regents of the University of Minnesota to develop safe and broadly protective vaccines against New World arenaviruses. The objective is to leverage a non-pathogenic arenavirus vector called RP18TRI to create live-attenuated vaccine candidates expressing antigens from the Junin and Machupo viruses. The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop an mRNA-based multivalent malaria vaccine. The project aims to optimize mRNA vaccine-induced antibody-mediated and cell-mediated immune responses targeting pre-erythrocytic and blood-stage malaria parasites. Specifically, the grant will support the design, production, and evaluation of mRNA vaccine candidates...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $207,262 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The grant supports the development of an mRNA vaccine against Bourbon virus, an emerging tick-borne RNA virus that can infect and cause disease in humans. The primary objectives are to evaluate the vaccine's efficacy in a mouse model and determine its mechanism of action. A...